660 related articles for article (PubMed ID: 3130534)
1. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.
Yasuda Y; Kikuchi T; Suzuki S; Tsutsui M; Yamada K; Hiyama T
Life Sci; 1988; 42(20):1941-54. PubMed ID: 3130534
[TBL] [Abstract][Full Text] [Related]
2. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S
J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
[TBL] [Abstract][Full Text] [Related]
3. Effect of 7-(3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy)- 2(1H)-quinolinone (OPC-4392), a newly synthesized agonist for presynaptic dopamine D2 receptor, on tyrosine hydroxylation in rat striatal slices.
Kiuchi K; Hirata Y; Minami M; Nagatsu T
Life Sci; 1988; 42(3):343-9. PubMed ID: 2892110
[TBL] [Abstract][Full Text] [Related]
4. Interactions of 7-[3-(4-[2,3-dimethylphenyl]piperazinyl)-propoxy]-2(1H)-quinolinone binding in rat striatum: effects of lesions.
Zhang X; Nakata Y; Kikuchi T; Segawa T
Pharm Res; 1990 Mar; 7(3):280-2. PubMed ID: 1971105
[TBL] [Abstract][Full Text] [Related]
5. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
Oshiro Y; Sato S; Kurahashi N; Tanaka T; Kikuchi T; Tottori K; Uwahodo Y; Nishi T
J Med Chem; 1998 Feb; 41(5):658-67. PubMed ID: 9513593
[TBL] [Abstract][Full Text] [Related]
6. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
Claustre Y; Fage D; Zivkovic B; Scatton B
J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
Martin GE; Haubrich DR; Williams M
Eur J Pharmacol; 1981 Nov; 76(1):15-23. PubMed ID: 7318920
[TBL] [Abstract][Full Text] [Related]
8. Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats.
Fujikawa M; Nagashima M; Inoue T; Yamada K; Furukawa T
Pharmacol Biochem Behav; 1996 Apr; 53(4):903-9. PubMed ID: 8801596
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development.
Neal BS; Joyce JN
Brain Res Dev Brain Res; 1991 Jun; 60(2):105-13. PubMed ID: 1832593
[TBL] [Abstract][Full Text] [Related]
10. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
[TBL] [Abstract][Full Text] [Related]
12. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
13. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
Arnt J
Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283
[TBL] [Abstract][Full Text] [Related]
14. Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M
Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734
[TBL] [Abstract][Full Text] [Related]
15. Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptors in vitro.
Mulder AH; Draper R; Sminia P; Schoffelmeer AN; Stoof JC
Eur J Pharmacol; 1985 Jan; 107(3):291-7. PubMed ID: 3979429
[TBL] [Abstract][Full Text] [Related]
16. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats.
Arnt J; Hyttel J
J Neural Transm; 1984; 60(3-4):205-23. PubMed ID: 6441835
[TBL] [Abstract][Full Text] [Related]
17. Postsynaptic striatal dopamine agonist or antagonist actions of (+) or (-) 3-PPP and modification after receptor deafferentation.
Oberlander C; Boissier JR
J Pharmacol; 1983; 14(4):401-4. PubMed ID: 6423905
[TBL] [Abstract][Full Text] [Related]
18. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine.
Clark D; Salah RS; Galloway MP
Synapse; 1991 Jul; 8(3):169-76. PubMed ID: 1948667
[TBL] [Abstract][Full Text] [Related]
19. Evidence for multiple dopamine receptors involved in the modulation of acetylcholine release in the striatum.
Hársing LG; Vizi ES
Pol J Pharmacol Pharm; 1985; 37(3):383-96. PubMed ID: 2866504
[TBL] [Abstract][Full Text] [Related]
20. Caffeine produces contralateral rotation in rats with unilateral dopamine denervation: comparisons with apomorphine-induced responses.
Herrera-Marschitz M; Casas M; Ungerstedt U
Psychopharmacology (Berl); 1988; 94(1):38-45. PubMed ID: 3126526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
